Today: 11 June 2026
Gold price steadies after record-high retreat as silver rebounds in thin year-end trade
30 December 2025
1 min read

Gold price steadies after record-high retreat as silver rebounds in thin year-end trade

NEW YORK, December 30, 2025, 02:06 ET

Gold prices steadied in Asian trade on Tuesday after a sharp retreat from record highs, as investors trimmed year-end positions and looked ahead to fresh U.S. policy signals. Spot gold was up 0.7% at $4,362.30 an ounce by 00:12 ET, while U.S. gold futures rose 0.8% to $4,378.75.

The volatility has been even sharper in silver, where thin holiday trading has magnified moves. After hitting a record of about $84 an ounce, silver fell 8.7% in its biggest one-day drop since August 2020 before bouncing about 2.5% on Tuesday to around $74.1, Reuters reported. “We’ve had a cooling in the precious metals, but I don’t think this trend is over,” said Tony Sycamore, an analyst at IG, noting the Chicago Mercantile Exchange raised margin requirements — the cash traders must post to hold futures positions. Reuters

The selloff matters because forced selling can accelerate when exchanges lift margin, and when liquidity is thin fewer orders are available to absorb big trades. That can turn routine profit-taking — investors selling after a rally to lock in gains — into outsized, fast price swings.

In U.S. trading on Monday, spot gold slid 4.5% to $4,330.79 an ounce after touching a record $4,549.71 on Friday, while February futures settled 4.6% lower at $4,343.60. Platinum dropped 14.5% to $2,096.53 after touching a record $2,478.50 earlier in the session, and palladium fell 15.9% to $1,617.47. Gold has risen about 65% this year, Reuters said.

Gold’s pullbacks often hinge on the outlook for interest rates because bullion does not pay interest. Expectations for lower rates can support the metal by reducing the opportunity cost of holding it, while higher-rate expectations can weigh.

Traders are also balancing profit-taking against persistent demand for gold as a store of value when political and military risks rise. That “safe-haven” bid can offset selling, especially when markets are sensitive to headlines.

In Europe, Russia’s Vladimir Putin told U.S. President Donald Trump that Moscow would review its position in peace negotiations after what the Kremlin described as a Ukrainian drone attack on one of Putin’s residences; Ukraine denied the claim.

In Asia, China fired rockets towards Taiwan during war games that Reuters said simulated a blockade, as Beijing staged its biggest drills around the island to date. Taiwan said debris entered its contiguous zone and its president condemned the drills.

Investors are now waiting for the next data point that can reset rate expectations: minutes from the Federal Reserve’s latest policy meeting due later Tuesday. Those minutes can move the U.S. dollar and Treasury yields, which in turn can shift demand for precious metals.

For silver and platinum, the story is not just macro policy. Both metals also have heavy industrial use, which can amplify volatility when traders reassess growth prospects or when manufacturers and investors adjust hedges.

Stock Market Today

  • Ford Stock Down 6% Over Five Years Amid Strategic Shift
    June 11, 2026, 10:58 AM EDT. Ford's stock has fallen 6% over five years, significantly underperforming the S&P 500's 71% gain despite a recent 20% rally. The company exited costly electric vehicle (EV) programs, launching Ford Energy to produce lithium-ion phosphate batteries for energy storage through a partnership with China's CATL. Investors remain cautious, focusing on Ford's reliance on domestic sales of its F-Series gas-powered trucks, its longstanding best-seller. Ford's strategic pivot away from EVs, admitting Chinese EV competition risks, and modest international presence contribute to lingering investor skepticism about its long-term value.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers
Previous Story

AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers

Nvidia stock dips after AI21 Labs talk report as NVDA investors size up Intel stake
Next Story

Nvidia stock dips after AI21 Labs talk report as NVDA investors size up Intel stake

Go toTop